The Department of Infectious Diseases at the Medical College of Georgia at Augusta University conducts Clinical Trials relating to a wide variety of pertinent infectious diseases. The following is a non-comprehensive list of currently active studies in the department. If you are interested in learning more about a specific study, please contact the study coordinator listed for the study and we would be more than happy to provide you will further details.

Official Title

Primary Investigator 

Study Coordinator

Evaluation of the Efficacy and Safety of PTC299 in Hospitalized Subjects With COVID-19 (FITE19)  Jose Vazquez Aprile Osborn
NCT04340388 Contribution of the Integrase Inhibitor Dolutegravir to Obesity and Cardiovascular Disease in Persons Living With HIV   Jonell Poe Ryan Harris
Amber Ladak
Reva Crandall
Jacob Looney


A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effects of EDP-938 in Adult Hematopoietic Cell Transplant Recipients With Acute Respiratory Syncytial Virus Infection of the Upper Respiratory Tract  Andrew Chao Aprile Osborn
NCT04442737 A Phase 4, Randomized, Active-Controlled, Open-label Study to Evaluate the Safety and Tolerability of Switching to Once-Daily Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-dose Combination (FDC) Regimen in Virologically-suppressed Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Experiencing Rapid Weight Gain With an INI + TAF/FTC ARV Regimen Cheryl Newman Angela Stroman
NCT03059992 Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI) Jose Vazquez Aprile Osborn
NCT04160468 A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single Dose of Exebacase in Patients Receiving Standard-of-Care Antibiotics for the Treatment of Staphylococcus Aureus Bloodstream Infections (Bacteremia), Including Right-Sided Infective Endocarditis (DISRUPT)  Jose Vazquez Aprile Osborn
NCT04650087 ACTIV-4C: A multicenter, adaptive, prospective, randomized trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge Jose Vazquez Ashton Bowles
NCT02735707 Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) Jose Vazquez Ashton Bowles